Clinical study of pranlukast as early seasonal treatment for Japanese cedar pollinosis

Clinical study of pranlukast as early seasonal treatment for Japanese cedar pollinosis - Clinical study of pranlukast as early seasonal treatment for Japanese cedar pollinosis(EIPP:Early Intervention of Pollinosis with Pranlukast)

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000583

Enrollment

200

Registered

2007-02-05

Start date

2007-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese cedar pollinosis

Interventions

Medical treatment is started before the beginning of pollen scattering. Two pranlukast capsules twice a day, after breakfast and dinner (total 4 pranlukast capsules/day) are orally administered from 3

Practical Guideline for the Management of Allergic Rhinitis in Japan&quot

from 17th or 18th Feb. to 31st Mar. or 1st Apr. Medical treatment is started before the beginning of pollen scattering. Two placebo capsules twice a day, after breakfast and dinner (total 4 placebo

from 17th or 18th Feb. to 31st Mar. or 1st Apr.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) a history of Japanese cedar pollinosis last year 2) differential diagnosis by rhinoscopy test 3) positive allergy test to Japanese cedar pollen 4) mild nasal symptoms, especially stuffy nose , with pollinosis

Exclusion criteria

Exclusion criteria: 1) any other disease, nasal polyp, acute/chronic rhinitis, sinusitis et al 2) use of any anti-histamine drugs, anti-allergy drugs, nasal steroid drugs et al at the beginning of the study 3) buildup phase of immunotherapy to Japanese cedar pollen 4) pregnancy, potential pregnancy, or lactation 5) the others, inappropriate to this study by the judgment of doctor

Design outcomes

Primary

Measure	Time frame
Symptom-medication score (symptomscore+medication score)	—

Secondary

Measure	Time frame
Symptom score (stuffy nose,runny nose, sneezing,eye itchiness and tearing), medication score and QOL Questionaire score(JRQLQ No1)	—

Countries

Japan

Contacts

Public ContactToru Okawa

Chiba University Graduate School of Medicine Department of Otorhinolaryngology

043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026